The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer

被引:9
|
作者
Schippinger, W
Regitnig, P
Bauernhofer, T
Ploner, F
Hofmann, G
Krippl, P
Wehrschütz, M
Lax, S
Carney, W
Neumann, R
Wernecke, KD
Samonigg, H
机构
[1] Graz Univ, Med Klin, Klin Abt Onkol, Dept Internal Med,Div Oncol, A-8036 Graz, Austria
[2] Graz Univ, Med Klin, Dept Pathol, A-8036 Graz, Austria
[3] Graz Univ, Med Klin, Dept Radiol, A-8036 Graz, Austria
[4] Humboldt Univ, Inst Med Biometry, D-13344 Berlin, Germany
[5] Bayer Vital GmbH, Rainer Neumann, D-51368 Leverkusen, Germany
[6] Bayer Diagnost, Oncogene Sci, Cambridge, MA 02142 USA
关键词
breast cancer; serum HER-2/neu; prognostic factors;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to determine the impact of serum HER-2/neu level dynamics during the course of disease and treatment on the prognosis of patients with metastatic breast cancer. Two thousand and thirty-eight serum samples collected sequentially after disease relapse in 286 patients with metastatic breast cancer were measured by Bayer Immuno I(TM) assay retrospectively for serum HER-2/neu (cut-off level 15 ng/ml). One hundred and five patients (37%) presented with serum HER-2/neu continuously less than or equal to15 ng/ml after disease recurrence, 71 (25%) had continuously elevated levels and 110 patients (38%) had both non-elevated and elevated values in the course of metastatic breast cancer. Patients with continuously elevated serum HER-2/neu levels had a significantly poorer survival after disease recurrence compared to patients with continuously or temporarily non-elevated serum HER-2/neu values (log-rank test: p<0.001). Including the number of palliative antitumor therapies and therapy response in Cox regression analysis, serum HER-2/neu dynamics revealed to be an independent prognostic factor for survival. In conclusion, 63% of 286 patients with metastatic breast cancer demonstrated either continuously or temporarily elevated serum HER-2/neu levels. Decrease of elevated serum HER-2/neu to levels less than or equal to15 ng/ml and levels continuously less than or equal to15 ng/ml during the course of disease correlated significantly with longer survival.
引用
收藏
页码:1331 / 1336
页数:6
相关论文
共 50 条
  • [31] Monitoring Serum HER-2/neu levels in metastatic breast cancer patients undergoing herceptin therapy regimens.
    Carney, WP
    Brown-Shimer, S
    Lin, D
    Schwartz, MK
    CLINICAL CHEMISTRY, 2003, 49 (06) : A100 - A100
  • [32] Monitoring serum HER-2/neu levels in metastatic breast cancer patients undergoing Herceptin® therapy regimens.
    Brown-Shimer, SL
    Schwartz, MK
    Schwartz, D
    Lin, D
    Carney, WP
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S111 - S111
  • [33] Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy
    Sandri, Maria Teresa
    Johansson, Harriet Ann
    Zorzino, Laura
    Salvatici, Michela
    Passerini, Rita
    Maisonneuve, Patrick
    Rocca, Andrea
    Peruzzotti, Giulia
    Colleoni, Marco
    CANCER, 2007, 110 (03) : 509 - 517
  • [34] HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma
    Ioannis Kalogiannidis
    Stamatios Petousis
    Mattheos Bobos
    Chrysoula Margioula-Siarkou
    Maria Topalidou
    Alexis Papanikolaou
    Ignace Vergote
    Theodoros Agorastos
    Archives of Gynecology and Obstetrics, 2014, 290 : 1231 - 1237
  • [35] HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma
    Kalogiannidis, Ioannis
    Petousis, Stamatios
    Bobos, Mattheos
    Margioula-Siarkou, Chrysoula
    Topalidou, Maria
    Papanikolaou, Alexis
    Vergote, Ignace
    Agorastos, Theodoros
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2014, 290 (06) : 1231 - 1237
  • [36] Her-2/neu and topoisomerase IIaexpression in primary and metastatic breast cancer
    Cardoso F.
    Breast Cancer Research, 3 (1)
  • [37] Prognostic and predictive impact of the HER-2/neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer
    Müller, V
    Witzel, I
    Lück, HJ
    Köhler, G
    von Minckwitz, G
    Möbus, V
    Sattler, D
    Wilczak, W
    Löning, T
    Jänicke, F
    Pantel, K
    Thomssen, C
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 86 (01) : 9 - 18
  • [38] Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer
    Volkmar Müller
    Isabell Witzel
    Hans Joachim Lück
    Günter Köhler
    Gunther von Minckwitz
    Volker Möbus
    Daniel Sattler
    Waldemar Wilczak
    Thomas Löning
    Fritz Jänicke
    Klaus Pantel
    Christoph Thomssen
    Breast Cancer Research and Treatment, 2004, 86 : 9 - 18
  • [39] HER-2/NEU EXPRESSION - A MAJOR PROGNOSTIC FACTOR IN ENDOMETRIAL CANCER
    HETZEL, DJ
    WILSON, TO
    KEENEY, GL
    ROCHE, PC
    CHA, SS
    PODRATZ, KC
    GYNECOLOGIC ONCOLOGY, 1992, 47 (02) : 179 - 185
  • [40] Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer
    Ali, SM
    Leitzel, K
    Chinchilli, VM
    Engle, L
    Demers, L
    Harvey, HA
    Carney, W
    Allard, JW
    Lipton, A
    CLINICAL CHEMISTRY, 2002, 48 (08) : 1314 - 1320